Veradermics reports Phase III male pattern hair loss data for its oral minoxidil extended-release tablet, with target area hair count rising from month two. Target area hair count reached 43.9 at month 12, and no treatment-related serious adverse events were seen. The company expects to topline its Phase III female pattern hair loss trial in the first half of 2027.
MANE · Veradermics, Inc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 76%
- Last earnings
- Oct 19, 2026
- Latest filing
- 10-Q · Nov 10
- Price history
- Feb 2026 to Nov 2026
The closing range uses available history since Feb 4, 2026; less than a full year is stored.
Up next
Latest documents
Veradermics reported positive Study ‘304’ Phase 3 results for VDPHL01 in male pattern hair loss. Nine-month net loss was $71.7 million, while $798.4 million of cash, cash equivalents and marketable securities was expected to fund operations into 2030.
Veradermics reported a third-quarter net loss of $21.0 million, versus $20.1 million a year earlier, with $798.4 million in cash and marketable securities. It also announced positive 12-month topline data from Study '302' for VDPHL01 in men.
Veradermics reported positive 12-month Study ‘302’ results for VDPHL01: non-vellus hair count increased 43.9 hairs/cm2 with twice-daily dosing and 29.7 hairs/cm2 with once-daily dosing; no new safety signals or treatment-related SAEs were observed.
Veradermics reported positive topline results from Study ‘304’, a placebo-controlled trial of VDPHL01 in men with mild-to-moderate pattern hair loss, meeting all primary and secondary endpoints. Non-vellus hair count rose 28.6 hairs/cm² on once-daily dosing and 36.4 hairs/cm² on twice-daily dosing, versus 6.6 hairs/cm² for placebo at Month 6. No treatment-related serious adverse events were observed.
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Jul 15, 2026TL;DR. Veradermics reported positive Phase 2 Study 207 results for VDPHL01 in female pattern hair loss, showing robust hair count gains and high patient-reported improvement with no cardiac safety signals, and completed enrollment in the registration-directed Phase 2/3 Study 306 with topline readout now guided to 1H27; quarterly net loss widened to $23.5M with higher opex while cash position strengthened to $819.9M, funding operations into 2030.
- + Positive Phase 2 Study 207 results showed robust hair count gains in female pattern hair loss with VDPHL01.
- + High patient-reported improvement in hair coverage supports strong efficacy profile.
- + No cardiac safety signals or treatment-related SAEs observed in female Phase 2 study.
- + Completed enrollment in 556-participant registration-directed Phase 2/3 Study 306 in females.
- + Cash position of $819.9M is expected to fund operations into 2030 through Phase 3 readouts and potential commercial launch.
- − Net loss widened to $23.5M in Q2 2026 from $15.6M in Q2 2025 on higher operating expenses.
- − R&D and G&A expenses increased significantly year-over-year as headcount and commercial readiness ramped.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Mean increase in non-vellus target area hair count (TAHC), BID dose arm, Study 302 continued gro | 43.9 | Month 12 | — |
| Mean increase in non-vellus target area hair count (TAHC), BID dose arm, Study 304 | 36.4 | Month 6 | — |
| Mean increase in non-vellus target area hair count (TAHC), QD dose arm, Study 302 continued grou | 29.7 | Month 12 | — |
| Mean increase in non-vellus target area hair count (TAHC), QD dose arm, Study 304 | 28.6 | Month 6 | — |
| Total potentially dilutive shares | 5,530,902 | the three months ended September 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MANE
this stock
Veradermics, Inc
|
$5.04B | — | — | — | 8.0% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 19, 2026
- This year
- 24
Veradermics reports Phase III male pattern hair loss data for its oral minoxidil extended-release tablet, with target area hair count rising from month two. Target area hair count reached 43.9 at month 12, and no treatment-related serious adverse events were seen. The company expects to topline its Phase III female pattern hair loss trial in the first half of 2027.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MANE | -7.8% | -13.9% | +21.7% | -14.4% | — |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | +0.7% | -4.7% | +30.9% | -5.7% | — |